Intravitreal Mitomycin C-Corticosteroids Conjugate in Inhibition. of Experimental Proliferative Vitreoretinopathy in an Ailimal Model

Abstract

Objectives: To determine the toxicity, efficacy, pharmacokinetics and pharmacodynamics of a novel intravitreal sustained-release Mitomycin C - Corticosteroids (Triamcinolone acetonide) (MMCffA) conjugate in the treatment of experimental proliferative vitreoretinopathy (PVR). Methods: The therapeutic efficacy and toxicity of the MMCff A conjugate were determined in a rabbit model that simulates human PVR. Intravitreal levels of MMC and TA were measured at different time points and drug release m vitro was tested. Toxic effects were evaluated by electroretinography, clinical examination, and light microscopy. Results: Both the severity of PVR grade and the percentage of eyes with moderate or worse tractional detachment were significantly less in eyes treated with the conjugate. The therapeutic effect of the intravitreal conjugate injection was paralleled by sustained intravitreal levels of triamcinolone and mitomycin. There were no drug related toxic effects evident on clinical or histopathological examination of the eyes receiving =<5.24ug (normal vitreous) and =<2.62 ug (vitrectomized) of the MMCffA

conjugate.